Brought to you by 
Fosun Pharma agrees to acquire generics company Gland Pharma; later revises deal terms
13 Aug 2020
Executive Summary
Shanghai Fosun Pharmaceutical Group Co. Ltd. agreed to acquire an 86% stake in generic injectables company Gland Pharma Ltd. for $1.26bn in cash. The shares are being purchased from KKR Floorline Investments (first invested in 2014) and other company shareholders. P.V.N. Raju, Gland's founder, and his son Dr. Ravi Penmetsa will retain a stake in the company.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fosun Pharma agrees to acquire generics company Gland Pharma; later revises deal terms
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice